State-of-the-art genetics panel optimizes kidney disease treatment
Answers from the Lab
Genetic factors play a role in at least 10% of adult cases of kidney disease and up to 70% of cases in children. In this test specific episode of the "Answers From the Lab" podcast, Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive and accurate results for optimal patient care.
"Our tests are among the most comprehensive diagnostic tests available. They utilize next generation sequencing for maximum depth of coverage and the highest possible detection rates across 302 genes, including technically challenging genes," Dr. Baudhin says.
The testing can identify potential underlying genetic causes of kidney disease and the specific type of kidney disease a patient has. "The results can then be used to guide treatment, inform prognosis and assess family members' risk," Thoreson says.
Unlike competitors' screening tests, Mayo Clinic Laboratories' panels are diagnostic. "You can trust them to identify an actual medical condition," Dr. Baudhin says. "Screening tests require clinical confirmation. The actual implications of the results are harder to understand."
Listen to learn more about Mayo Clinic Laboratories' renal genetics panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the blood proteins, for improved patient care and simpler test ordering.
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal health.